ATTENTION: HealthWell Foundation headquarters and hotline will be closed on Monday, January 20, 2025, in observance of the holiday and will re-open on Tuesday, January 21, 2025, at 9:00 a.m. We encourage you to continue to use our Patient, Pharmacy and Provider Portals during this time. If you have a question that cannot be answered by visiting the portal, please send an email to [email protected]. We appreciate your patience and look forward to serving you. The HealthWell Team
Myelodysplastic Syndromes - Medicare Access (Medicare patients only)
Status
OpenFund Type
CopayPremium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum CopayReimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium
Reimbursement Amount
Household Income Limit
500% of the Federal Poverty Level(adjusted for household size and high
cost of living areas)
Treatments Covered
- Aranesp
- Atgam
- Azacitidine
- Azacitidine Novaplus
- Dacogen
- Darbepoetin Alfa
- Decitabine Novaplus
- Epoetin Alfa
- Epogen
- Ethyol
- Gleevec
- Granix
- Hycamptin
- Imatinib Mesylate
- Inqovi
- Jakafi
- Leukine
- Luspatercept-aamt
- Neoral (oral Only)
- Neupogen
- Nivestym
- Nplate
- Onureg
- Premierpro Rx Azacitadine
- Premierpro Rx Decitabine
- Procrit
- Promacta
- Reblozyl
- Retacrit
- Revlimid
- Rytelo
- Sandimmune
- Thalomid
- Thymoglobulin
- Tibsovo
- Toposar
- Topotecan Hcl
- Tretinoin (oral Only)
- Trisenox
- Venclexta
- Vidaza
- Zarxio
Fund Definition
Assistance with the prescription drugs and biologics used in the treatment and management of Myelodysplastic Syndromes.
Grant Utilization
HealthWell estimates that patients use an average of $4,800 during their 12-month grant period for this disease area.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
-
To qualify for copayment assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. Please note that in order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Myelodysplastic Syndromes
According to the National Cancer Institute, myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy red blood cells, white blood cells, or platelets. These immature blood cells, called blasts, do not work the way they should and either die in the bone marrow or soon after they go into the blood. Source: National Cancer Institute
Additional Educational Resources
- Aplastic Anemia & MDS International Foundation
- MDS Foundation
- CancerCare
- American Cancer Society
- American Society of Clinical Oncology
- National Cancer Institute
- National Coalition for Cancer Survivorship
- National Infusion Center Association
You may also visit our Resource List to view other copayment organizations that may provide assistance.